<VariationArchive RecordType="classified" VariationID="15940" VariationName="NM_000516.7(GNAS):c.119_139+17del" VariationType="Deletion" Accession="VCV000015940" Version="1" NumberOfSubmissions="2" NumberOfSubmitters="1" DateLastUpdated="2023-12-25" DateCreated="2016-08-22" MostRecentSubmission="2016-08-22">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="30979" VariationID="15940">
      <GeneList>
        <Gene Symbol="GNAS" FullName="GNAS complex locus" GeneID="2778" HGNC_ID="HGNC:4392" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>20q13.32</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="20" Accession="NC_000020.11" start="58839748" stop="58911192" display_start="58839748" display_stop="58911192" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="20" Accession="NC_000020.10" start="57414794" stop="57486249" display_start="57414794" display_stop="57486249" Strand="+" />
          </Location>
          <OMIM>139320</OMIM>
          <Haploinsufficiency last_evaluated="2021-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GNAS">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GNAS">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_000516.7(GNAS):c.119_139+17del</Name>
      <CanonicalSPDI>NC_000020.11:58891844:CGCACCGCCTGCTGCTGCTGGGTAAGGGCGGGCGGGGG:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>20q13.32</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="20" Accession="NC_000020.11" start="58891845" stop="58891882" display_start="58891845" display_stop="58891882" variantLength="38" positionVCF="58891844" referenceAlleleVCF="ACGCACCGCCTGCTGCTGCTGGGTAAGGGCGGGCGGGGG" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="20" Accession="NC_000020.10" start="57466900" stop="57466937" display_start="57466900" display_stop="57466937" variantLength="38" positionVCF="57466899" referenceAlleleVCF="ACGCACCGCCTGCTGCTGCTGGGTAAGGGCGGGCGGGGG" alternateAlleleVCF="A" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000020.10" sequenceAccession="NC_000020" sequenceVersion="10" change="g.57466900_57466937del" Assembly="GRCh37">
            <Expression>NC_000020.10:g.57466900_57466937del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000020.11" sequenceAccession="NC_000020" sequenceVersion="11" change="g.58891845_58891882del" Assembly="GRCh38">
            <Expression>NC_000020.11:g.58891845_58891882del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_016194.2" sequenceAccession="NG_016194" sequenceVersion="2" change="g.57106_57143del">
            <Expression>NG_016194.2:g.57106_57143del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_016592.5" sequenceAccession="NM_016592" sequenceVersion="5" change="c.*43-3767_*43-3730del" MANEPlusClinical="true">
            <Expression>NM_016592.5:c.*43-3767_*43-3730del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001309861.2" sequenceAccession="NM_001309861" sequenceVersion="2" change="c.-38-3767_-38-3730del">
            <Expression>NM_001309861.2:c.-38-3767_-38-3730del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001077490.3" sequenceAccession="NM_001077490" sequenceVersion="3" change="c.*1-3767_*1-3730del">
            <Expression>NM_001077490.3:c.*1-3767_*1-3730del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_080425.4" sequenceAccession="NM_080425" sequenceVersion="4" change="c.2069-3767_2069-3730del" MANEPlusClinical="true">
            <Expression>NM_080425.4:c.2069-3767_2069-3730del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001309883.1" sequenceAccession="NM_001309883" sequenceVersion="1" change="c.*159-3767_*159-3730del">
            <Expression>NM_001309883.1:c.*159-3767_*159-3730del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001309840.2" sequenceAccession="NM_001309840" sequenceVersion="2" change="c.-39+2492_-39+2529del">
            <Expression>NM_001309840.2:c.-39+2492_-39+2529del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001077488.5" sequenceAccession="NM_001077488" sequenceVersion="5" change="c.119_139+17del">
            <Expression>NM_001077488.5:c.119_139+17del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000516.7" sequenceAccession="NM_000516" sequenceVersion="7" change="c.119_139+17del" MANESelect="true">
            <Expression>NM_000516.7:c.119_139+17del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_080426.4" sequenceAccession="NM_080426" sequenceVersion="4" change="c.119_139+17del">
            <Expression>NM_080426.4:c.119_139+17del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001077489.4" sequenceAccession="NM_001077489" sequenceVersion="4" change="c.119_139+17del">
            <Expression>NM_001077489.4:c.119_139+17del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001309842.2" sequenceAccession="NM_001309842" sequenceVersion="2" change="c.119_139+17del">
            <Expression>NM_001309842.2:c.119_139+17del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2145916749" DB="dbSNP" />
        <XRef Type="Allelic variant" ID="139320.0015" DB="OMIM" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000516.7(GNAS):c.119_139+17del AND Pseudohypoparathyroidism" Accession="RCV000017305" Version="28">
        <ClassifiedConditionList TraitSetID="5179">
          <ClassifiedCondition DB="MedGen" ID="C0033806">Pseudohypoparathyroidism</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="1998-03-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000516.7(GNAS):c.119_139+17del AND Pseudopseudohypoparathyroidism" Accession="RCV000017304" Version="24">
        <ClassifiedConditionList TraitSetID="5180">
          <ClassifiedCondition DB="MedGen" ID="C0033835">Pseudopseudohypoparathyroidism</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="1998-03-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="1998-03-01" NumberOfSubmissions="2" NumberOfSubmitters="1" DateCreated="2016-08-22" MostRecentSubmission="2016-08-22">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">9506752</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="5180" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4060" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Pseudopseudohypoparathyroidism</ElementValue>
                <XRef ID="Pseudopseudohypoparathyroidism/6049" DB="Genetic Alliance" />
                <XRef ID="MONDO:0012912" DB="MONDO" />
                <XRef ID="237659007" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Albright hereditary osteodystrophy without multiple hormone resistance</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PPHP</ElementValue>
                <XRef Type="MIM" ID="612463" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7860" />
                <XRef ID="7860" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="79445" DB="Orphanet" />
              <XRef ID="C0033835" DB="MedGen" />
              <XRef ID="MONDO:0012912" DB="MONDO" />
              <XRef Type="MIM" ID="612463" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="5179" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3403" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Pseudohypoparathyroidism</ElementValue>
                <XRef ID="HP:0000852" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0019992" DB="MONDO" />
                <XRef ID="58976002" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHP1A</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10758" />
                <XRef ID="10758" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="79443" DB="Orphanet" />
              <XRef ID="97593" DB="Orphanet" />
              <XRef ID="C0033806" DB="MedGen" />
              <XRef ID="MONDO:0019992" DB="MONDO" />
              <XRef Type="primary" ID="HP:0000852" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="37577" SubmissionDate="2016-08-05" DateLastUpdated="2016-08-22" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="139320.0015_PSEUDOHYPOPARATHYROIDISM, TYPE IA" title="GNAS, 38-BP DEL, EX1/IVS1 BOUNDARY_PSEUDOHYPOPARATHYROIDISM, TYPE IA" />
        <ClinVarAccession Accession="SCV000037577" DateUpdated="2016-08-22" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1998-03-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to included disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In affected members of a large kindred in which 2 mothers had pseudopseudohypoparathyroidism (PPHP; 612463) and their 6 offspring had PHP Ia (103580), Fischer et al. (1998) identified a 38-bp deletion at the exon 1/intron 1 boundary of the GNAS gene. The deletion was predicted to eliminate the splice donor site of exon 1. Some of the patients had increased basal serum levels of thyroid-stimulating hormone (TSH; see 188540) and/or excessive TSH responses to thyrotropin-releasing hormone (TRH; 613879). The pseudo-PHP patients had decreased Gs activity, but normal urinary cAMP responses to PTH, normal TSH levels and responses to TRH, and normal serum levels of calcium and PTH.</Attribute>
              <Citation>
                <ID Source="PubMed">9506752</ID>
              </Citation>
              <XRef DB="OMIM" ID="612463" Type="MIM" />
              <XRef DB="OMIM" ID="103580" Type="MIM" />
              <XRef DB="OMIM" ID="188540" Type="MIM" />
              <XRef DB="OMIM" ID="613879" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNAS" />
          </GeneList>
          <Name>GNAS, 38-BP DEL, EX1/IVS1 BOUNDARY</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">38-BP DEL, EX1/IVS1 BOUNDARY</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="139320.0015" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="included">PSEUDOHYPOPARATHYROIDISM, TYPE IA</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="37576" SubmissionDate="2016-08-05" DateLastUpdated="2016-08-22" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="139320.0015_PSEUDOPSEUDOHYPOPARATHYROIDISM" title="GNAS, 38-BP DEL, EX1/IVS1 BOUNDARY_PSEUDOPSEUDOHYPOPARATHYROIDISM" />
        <ClinVarAccession Accession="SCV000037576" DateUpdated="2016-08-22" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1998-03-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In affected members of a large kindred in which 2 mothers had pseudopseudohypoparathyroidism (PPHP; 612463) and their 6 offspring had PHP Ia (103580), Fischer et al. (1998) identified a 38-bp deletion at the exon 1/intron 1 boundary of the GNAS gene. The deletion was predicted to eliminate the splice donor site of exon 1. Some of the patients had increased basal serum levels of thyroid-stimulating hormone (TSH; see 188540) and/or excessive TSH responses to thyrotropin-releasing hormone (TRH; 613879). The pseudo-PHP patients had decreased Gs activity, but normal urinary cAMP responses to PTH, normal TSH levels and responses to TRH, and normal serum levels of calcium and PTH.</Attribute>
              <Citation>
                <ID Source="PubMed">9506752</ID>
              </Citation>
              <XRef DB="OMIM" ID="612463" Type="MIM" />
              <XRef DB="OMIM" ID="103580" Type="MIM" />
              <XRef DB="OMIM" ID="188540" Type="MIM" />
              <XRef DB="OMIM" ID="613879" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNAS" />
          </GeneList>
          <Name>GNAS, 38-BP DEL, EX1/IVS1 BOUNDARY</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">38-BP DEL, EX1/IVS1 BOUNDARY</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="139320.0015" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">PSEUDOPSEUDOHYPOPARATHYROIDISM</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="37576" TraitType="Disease" MappingType="Name" MappingValue="PSEUDOPSEUDOHYPOPARATHYROIDISM" MappingRef="Preferred">
        <MedGen CUI="C0033835" Name="Pseudopseudohypoparathyroidism" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="37577" TraitType="Disease" MappingType="Name" MappingValue="PSEUDOHYPOPARATHYROIDISM, TYPE IA" MappingRef="Alternate">
        <MedGen CUI="C3494506" Name="Pseudohypoparathyroidism type I A" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

